Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
4.88M
-
Shares change
-
+4.07M
-
Total reported value, excl. options
-
$52.9M
-
Value change
-
+$44.1M
-
Number of buys
-
11
-
Price
-
$10.84
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q3 2021
12 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2021.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.88M shares
of 49.6M outstanding shares and own 9.84% of the company stock.
Largest 10 shareholders include FMR LLC (2.5M shares), FRANKLIN RESOURCES INC (1.13M shares), Sands Capital Ventures, LLC (812K shares), VANGUARD GROUP INC (214K shares), Woodline Partners LP (100K shares), CAAS CAPITAL MANAGEMENT LP (50K shares), STATE STREET CORP (26.6K shares), BlackRock Inc. (22.3K shares), GEODE CAPITAL MANAGEMENT, LLC (20.4K shares), and MILLENNIUM MANAGEMENT LLC (10.6K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.